Cellectar reports financial results for first quarter 2022 and provides a corporate update

Florham park, n.j., may 10, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended march 31, 2022 and provided a corporate update.

CLRB Ratings Summary

CLRB Quant Ranking